Greater body mass index has been convincingly related to increased endometrial cancer risk, however, whether adiposity earlier in life or abdominal fatness, is an independent risk factor and whether weight gain or greater height increases the risk is not clear.
As part of the Continuous Update Project of the World Cancer Research Fund
International we conducted a systematic review and meta analysis of prospective studies of the association between anthropometric measures and endometrial cancer risk and searched PubMed and several other databases up to February 2015. Summary relative risks were calculated using a random effects model. Thirty prospective studies of BMI and endometrial cancer risk with 22320 cases among 6445402 participants were included. The summary relative risk (RR) for a 5 unit increment was 1.54 (95% CI: 1.47 1.61, I 2 =81%). Although the test for nonlinearity was significant, p nonlinearity <0.0001, and the curve was steeper within the overweight and obese BMI ranges, there was evidence of increased risk even within the high normal BMI range. All measures of adiposity were associated with increased risk of endometrial cancer, and in addition increasing height was associated with increased risk.
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Although there is strong evidence that general adiposity increases endometrial cancer risk, the evidence for an association between adiposity at younger ages, abdominal fatness, weight gain and greater height in relation to endometrial cancer risk is less substantial. This meta analysis reinforces the importance of weight control in the prevention of endometrial cancer. Greater body fatness as measured by body mass index (BMI=kg of weight/height in metres 2 ) has been associated with increased risk of endometrial cancer in a large number of studies (4 13). In the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) report from 2007 it was stated that the evidence that greater body fatness increases endometrial cancer risk was convincing (14). However, it is unclear whether greater BMI in early adulthood is more strongly associated with endometrial cancer, than BMI in mid life and whether an association between early adulthood BMI is independent of mid life BMI. In addition, greater abdominal fatness as measured by waist to hip ratio or waist circumference was probably associated with increased risk, but the few prospective studies available at that time limited the strength of the conclusions (14). Whether or not abdominal adiposity and overall adiposity independently of each other are associated with increased risk is also not known. In addition, several studies have assessed the association between weight changes between early adulthood and middle age in relation to endometrial cancer risk and these studies have indicated an increased risk with greater weight gain. If specific adiposity related variables are more strongly associated with endometrial cancer than others it could provide more detailed and improved recommendations for endometrial cancer prevention as well as possible insights into underlying biological mechanisms. Relatively few studies had assessed height in relation to endometrial cancer at that time (5;8;15;16) hip ratio level in each category was assigned to the corresponding relative risk for each study and for studies that reported these measures by ranges we estimated the mean in each category using the method described by Chene and Thompson (56). For studies which did not use the lowest category as the reference category we converted the risk estimates so that the lowest category became the reference category using the method by Hamling (57). A potential nonlinear dose response relationship between BMI, waist circumference and waist to hip ratio and endometrial cancer was examined by using fractional polynomial models (58). We determined the best fitting second order fractional polynomial regression model, defined as the one with the lowest deviance. A likelihood ratio test was used to assess the difference between the nonlinear and linear models to test for nonlinearity (58).
Subgroup and meta regression analyses were conducted to investigate potential sources of heterogeneity and heterogeneity between studies was quantitatively assessed by the Q test and I 2 (59). Study quality was assessed using the Newcastle Ottawa scale (60). Small Table 11 ). There was little evidence of heterogeneity in subgroup analyses ( Table 2 ).
Study quality and sensitivity analyses
There was no evidence that the results differed when stratified by study quality scores, and in general the study quality was high ( Table 1, Table 2 ). For example mean (median) study quality scores were 7.5 (8.0) for the analysis of BMI, 6.9 (7.0) for BMI in young adulthood, 7.0 (7.5) for weight, 7.3 (7.0) for weight gain, and 7.8 (8.0) for height, out of a maximum of 9
points. When excluding one study at a time none of the associations were materially altered
(Supplementary text). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 However, to our knowledge this is the first meta analysis to comprehensively assess several anthropometric measures including BMI in young adulthood, weight, weight changes, and abdominal measures of adiposity, to examine and quantify the independent effect of abdominal and overall adiposity, and to examine the shape of the dose response relationship between different measures of body fatness and endometrial cancer. Our results consistently show a dose response association of increasing risk with greater body fatness, and there appeared to be an independent association of BMI and waist circumference with endometrial cancer risk. Both BMI in young adulthood and weight gain between early adulthood and middle age was positively associated with endometrial cancer risk, the latter being consistent with a recent meta analysis (63). There was evidence of a nonlinear association in most of the analyses, and the increased risk appeared to be steeper at higher levels of exposure for BMI (>25 kg/m 2 ), weight (>65 70 kg) and waist circumference (>85 cm), while for BMI at ages 18 25, weight changes, and waist to hip ratio, as well as the analysis of BMI and endometrial cancer mortality the associations appeared to be linear above a certain point. However, there was evidence of increased endometrial cancer risk with increasing BMI even within the normal BMI range suggesting that relatively lean women (BMI around 20) have the lowest risk. There was evidence of effect modification by hormone replacement therapy use, which is an independent risk factor for endometrial cancer (77) , and the association was much stronger in never users than in ever users. This finding is expected, as circulating estrogens is a major factor in the relationship between body fatness and endometrial cancer (64;68).
Page 14 of 123 Annals of Oncology
Because circulating estrogen levels are mainly determined by the exogenous hormones in hormone therapy users, the potential for overweight and obesity to increase circulating estrogens and endometrial cancer risk is relatively smaller in hormone therapy users than in non users.
To our knowledge this is the first meta analysis of prospective studies to report a significantly increased risk of endometrial cancer with greater height. In the WCRF/AICR 2007 report there was only limited and suggestive evidence for an association between height and endometrial cancer risk (14), but in the current analysis six additional publications were included and this provided statistical power to detect an association. Although there is strong evidence for an association between greater height and increased risk of other cancers including cancers of the breast, colorectum, pancreas, and ovaries (14;78), the specific mechanism that may explain an association between greater height and endometrial cancer risk is not clear. Elevated levels of insulin like growth factor 1 (IGF 1) has been implicated in other cancers as it is an important determinant for growth and may inhibit apoptosis, stimulate cell proliferation and synthesis of sex steroids and inhibit the synthesis of SHBG (79) . Our meta analysis has some limitations which may affect the interpretation of the results. Although there was high heterogeneity in most of the adiposity related analyses this appeared to be attributable to differences in the strength of the association, rather than on differences in the directionality of effect as all studies apart from one reported risk estimates in the direction of increased risk. The positive associations observed persisted among almost all subgroup analyses. Another limitation is the low to moderate number of cohort studies available reporting on waist circumference, hip circumference and waist to hip ratio which limited our possibility to conduct subgroup analyses and test for publication bias for these measures. Although our analysis suggest that both high BMI and waist circumference increase endometrial cancer risk, few studies have conducted further adjustments between BMI and waist measures to try to clarify their independent role. This is a limitation and therefore needs further assessment in any future studies. In addition, further analyses of waist measures within strata of BMI (and vice versa) could clarify potential gains by using additional adiposity measures. It is not surprising that the association between BMI in young adulthood and endometrial cancer was attenuated among three studies which further adjusted for baseline BMI, because adiposity in early adulthood is highly correlated with adiposity in middle age (84 88) . The positive association between early adulthood BMI and endometrial cancer may therefore largely be mediated through a greater body size later in life. There were fewer studies in the analysis of height than in the analysis of BMI, and it is unclear whether this is due to selective publication bias or if the data were not analysed due to the lack of a previous hypothesis. Although it is possible that confounding may have affected the results as overweight and obese women usually are less physically active and have unhealthier diets than normal weight women, it is unlikely that such confounding could entirely explain the association because the risk associated with body fatness is much stronger than those observed for both physical activity and dietary factors. In addition, the results persisted in Measurement errors in the assessment of height and weight may have influenced our results. Most of the studies relied on self reported height and weight, however, there is generally a high correlation between self reported and measured height and weight (91) .
There was heterogeneity in the subgroup analysis of weight by whether or not the exposure was measured or self reported, with a weaker, but still significant association in the studies with measured weight compared to those with self reported weight. However, there was no heterogeneity in the association between BMI and endometrial cancer when stratified by the exposure assessment. Although meta analyses of published literature may be susceptible to publication bias, we found no evidence of publication bias with either Egger's test or with Begg's test or when visually inspecting the funnel plots.
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